{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Luye+Pharma+Group+Ltd.",
    "query": {
      "sponsor": "Luye Pharma Group Ltd."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 22,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Luye+Pharma+Group+Ltd.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T21:45:29.009Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03357796",
      "title": "Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "LY03005",
          "type": "DRUG"
        },
        {
          "name": "Pristiq",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2017-11-27",
      "completion_date": "2017-12-22",
      "has_results": false,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 1,
      "location_summary": "Eatontown, New Jersey",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03357796"
    },
    {
      "nct_id": "NCT02055287",
      "title": "Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "LY03004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-03",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-11-10",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 2,
      "location_summary": "Orange, California • Austin, Texas",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02055287"
    },
    {
      "nct_id": "NCT03733574",
      "title": "A Study of LY03005 vs Pristiq",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "LY03005",
          "type": "DRUG"
        },
        {
          "name": "Pristiq",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2018-06-19",
      "completion_date": "2018-07-26",
      "has_results": false,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03733574"
    },
    {
      "nct_id": "NCT02271412",
      "title": "Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder, Recurrent, Unspecified"
      ],
      "interventions": [
        {
          "name": "LY03005",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 58,
      "start_date": "2014-10",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-10-21",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 1,
      "location_summary": "Marlton, New Jersey",
      "locations": [
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02271412"
    },
    {
      "nct_id": "NCT02055300",
      "title": "Safety, Tolerability and Pharmacokinetics Study of LY03005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "LY03005",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Meal",
          "type": "OTHER"
        },
        {
          "name": "Pristiq",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 88,
      "start_date": "2014-02",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-11-10",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02055300"
    },
    {
      "nct_id": "NCT02603770",
      "title": "Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lipid Metabolism Disorder"
      ],
      "interventions": [
        {
          "name": "XueZhiKang",
          "type": "DRUG"
        },
        {
          "name": "Lovastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2015-11",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-12-05",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603770"
    },
    {
      "nct_id": "NCT04384666",
      "title": "A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)",
          "type": "DRUG"
        },
        {
          "name": "Neupro 4 mg / 24 Hr. Transdermal Patch",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-06-02",
      "completion_date": "2020-08-10",
      "has_results": false,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04384666"
    },
    {
      "nct_id": "NCT02055274",
      "title": "Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "LY03003",
          "type": "DRUG"
        },
        {
          "name": "Neupro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2013-10",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-10-21",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 5,
      "location_summary": "Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Douglasville",
          "state": "Georgia"
        },
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02055274"
    },
    {
      "nct_id": "NCT03589066",
      "title": "Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "LY03003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-05-15",
      "completion_date": "2018-10-31",
      "has_results": false,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 2,
      "location_summary": "Hallandale, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589066"
    },
    {
      "nct_id": "NCT02186769",
      "title": "An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Risperdal® Consta®",
          "type": "DRUG"
        },
        {
          "name": "LY03004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-07",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-06-18",
      "last_synced_at": "2026-10-03T21:45:29.009Z",
      "location_count": 2,
      "location_summary": "Orange County, California • Austin, Texas",
      "locations": [
        {
          "city": "Orange County",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186769"
    }
  ]
}